Key result
Smooth muscle cell-specific mineralocorticoid receptor deletion prevented obesity-induced coronary and cardiac diastolic dysfunction in female mice independent of blood pressure.
Why the study?
Coronary microvascular dysfunction predicts cardiac mortality in obesity, especially in females, and mineralocorticoid receptor antagonism may be more efficacious in obese female HFpEF patients.
Does smooth muscle cell-specific mineralocorticoid receptor deletion prevent obesity-associated coronary and cardiac diastolic dysfunction in female mice?
Does smooth muscle cell-specific mineralocorticoid receptor deletion prevent obesity-associated coronary and cardiac diastolic dysfunction in female mice?
Smooth muscle cell-specific mineralocorticoid receptor deletion protects female mice from obesity-induced coronary microvascular and cardiac diastolic dysfunction by attenuating cardiac inflammation.
Hypothesis-generating for SMC MR antagonism in obese female HFpEF; prospective trials needed before clinical adoption.
Coronary microvascular dysfunction (CMD) is associated with cardiac dysfunction and predictive of cardiac mortality in obesity, especially in females. Emerging evidence suggests development of heart failure with preserved ejection fraction in females with CMD and that mineralocorticoid receptor (MR) antagonism may be more efficacious in obese female, versus male, HFpEF patients. Accordingly, we examined the hypothesis that smooth muscle cell (SMC)-specific MR deletion prevents obesity-associated coronary and cardiac diastolic dysfunction in females. Obesity was induced in female mice via western diet (WD) feeding alongside littermates fed standard diet. Initial studies revealed that global MR blockade with spironolactone prevented impaired coronary vasodilation and diastolic dysfunction in obese females. Importantly, specific deletion of SMC-MR similarly prevented obesity-associated coronary and cardiac dysfunction. Cardiac gene expression profiling suggested reduced cardiac inflammation in WD-fed mice with SMC-MR deletion independent of blood pressure, aortic stiffening, and cardiac hypertrophy. Further mechanistic studies utilizing single-cell RNA sequencing of non-cardiomyocyte cell populations revealed novel impacts of SMC-MR deletion on the cardiac cellulome in obese mice. Specifically, WD feeding induced inflammatory gene signatures in multiple non-myocyte populations (B/T cells, macrophages, and endothelium), independent of cardiac fibrosis, that was prevented by SMC-MR deletion. Further, SMC-MR deletion induced a basal reduction in cardiac mast cells and prevented WD-induced cardiac pro-inflammatory chemokine expression and leukocyte recruitment. These data reveal a central role for SMC-MR signaling in obesity-associated coronary and cardiac dysfunction thus supporting the emerging paradigm of a vascular origin of cardiac dysfunction in obesity.
No takes yet. Share an insight, caveat, or question.
Dona et al. (2022) studied Obesity-associated coronary and cardiac diastolic dysfunction. Smooth muscle cell-specific mineralocorticoid receptor (SMC-MR) deletion vs. MR-Intact littermate mice was evaluated on Cardiac diastolic function and coronary vascular function. Smooth muscle cell-specific mineralocorticoid receptor deletion prevented obesity-induced coronary and cardiac diastolic dysfunction in female mice independent of blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: